ACHL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors...

Stats
Today's Volume	111 855
Average Volume	793 401
Market Cap	32.20M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $-0.460 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.450
ATR14	$0.00900 (1.15%)

Volume Correlation

Long: -0.37 (neutral)

Short: -0.50 (weak negative)

Signal:(50.707) Neutral

Achilles Therapeutics plc Correlation

10 Most Positive Correlations
STER	0.94
SVAC	0.939
AGLE	0.938
ELEV	0.925
ALZN	0.922
GANX	0.922
TSVT	0.918
PAIC	0.913
SEDG	0.912
ALGT	0.911

10 Most Negative Correlations
TSBK	-0.92
BLTE	-0.918
NETE	-0.912
MITA	-0.911
FANH	-0.906
SGII	-0.905
LOPE	-0.901
CHPM	-0.899
MTSI	-0.898
LWAC	-0.897

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Achilles Therapeutics plc Correlation - Currency/Commodity

0.29
( neutral )

0.13
( neutral )

0.00
( neutral )

-0.30
( neutral )

Achilles Therapeutics plc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-4.73M (0.00 %)
EPS:	$-1.750

Q4	2023
Revenue:	$0
Gross Profit:	$-1.16M (0.00 %)
EPS:	$-0.470

Q3	2023
Revenue:	$0
Gross Profit:	$-1.20M (0.00 %)
EPS:	$-0.420

Q2	2023
Revenue:	$0
Gross Profit:	$-1.30M (0.00 %)
EPS:	$-0.420

Financial Reports:

No articles found.

Achilles Therapeutics plc

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.